Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 9, 2025

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions
Cutaneous Leishmaniasis
Interventions
DRUG

Levofloxacin 0.5%

"Intralesional levofloxacin (5 mg/ml, 100 ml, Tavanic®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia was added. The solutions were injected intralesionally and not subcutaneously."

Trial Locations (1)

10047

RECRUITING

Mustansiriyah University, Baghdad

All Listed Sponsors
lead

Hayder Adnan Fawzi

OTHER